A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : VGC / valganciclovir

[Related PubMed/MEDLINE]
Total Number of Papers: 31
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   VGC  (>> Co-occurring Abbreviation)
Long Form:   valganciclovir
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Validation of an assay for quantifying ganciclovir in dried blood spots. CMV, DBS, GCV, NA
2018 Cytomegalovirus infection in heart transplantation: A single center experience. CMV
2018 High-Dose Acyclovir for Cytomegalovirus Prophylaxis in Seropositive Abdominal Transplant Recipients. ASOT, CMV, HDA, SPK
2015 Comparison between valganciclovir and aciclovir/valaciclovir for CMV prophylaxis in pediatric renal transplantation. ACV, CMV
2015 Oral Valganciclovir as Preemptive Therapy for Cytomegalovirus Reactivation in Pediatric Hematopoietic Stem Cell Transplant Patients. CMV, GCV, HSCT
2014 Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation. CMV, ETP, STP
2014 Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis. CI, CMV, GCV, SOTR
2013 Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation? ASCT, CMV, GCV
2012 Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. allo-HSCT, CMV, GCV
10  2012 Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. CMV, HSCT
11  2012 Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. CI, CMV
12  2012 Successful conversion to everolimus after cytomegalovirus infection in a heart transplant recipient. CMV, EVL
13  2011 Determination of Ganciclovir and its prodrug Valganciclovir by hydrophilic interaction liquid chromatography-tandem mass spectrometry. DBS, GCV, LLOQ, SRM
14  2011 Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. CI, OR
15  2011 Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. CMV
16  2010 High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection. CMV, HSCT
17  2010 Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients. HCMV
18  2010 Prophylactic therapy with valganciclovir in high-risk (cytomegalovirus D+/R-) kidney transplant recipients: a single-center experience. CMV
19  2010 Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial. CMV, HSCT, PCR
20  2009 Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report. EBV, PTLD
21  2009 Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. CMV, HSCT
22  2009 Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. GCV, GFR, NONMEM, TDM
23  2009 Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil. BMI, MELD, MMF
24  2008 Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. CMV, MMF
25  2007 Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in chinese cardiac recipients. CMV, WBC
26  2006 Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. CMV, GCV, HSCT
27  2005 Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. AA, CMV
28  2005 Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. CMV
29  2004 Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. CMV
30  2004 Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. ALA, CMV, GCV
31  2000 Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. CI, GCV, i.v, p.o